GLP-1s and Muscle Mass: What the Evidence Shows
GLP-1 medications like semaglutide and tirzepatide drive large weight loss. Some of what comes off is muscle-supporting tissue — here is what the evidence does, and doesn't, show.
By Wellness Wire Editorial
GLP-1 receptor agonists — semaglutide (sold as Wegovy) and tirzepatide (sold as Zepbound) — can produce dramatic weight loss. That success has raised a reasonable question: when the pounds come off, how much of the loss is fat, and how much is muscle? The short answer from the current evidence is broadly reassuring but incomplete. Most of the loss is fat, some is lean tissue, and the effect on actual muscle strength has barely been measured.
What the drugs do to your weight
The label says it plainly: greater fat loss than lean loss — but not fat only.
The clearest statement comes from the regulators. The FDA prescribing information for Wegovy notes in plain language that semaglutide "lowers body weight with greater fat mass loss than lean mass loss." The label for tirzepatide (Zepbound) carries an equivalent statement. That is the vetted framing: the weight these drugs remove is preferentially fat — but it is not fat only. Some lean tissue goes too, as it does with virtually any substantial weight loss, whether from dieting or bariatric surgery, because the body's supporting tissue shrinks as the body itself gets smaller.
Fat versus lean: what the scans show
DXA scans put roughly three-quarters of the loss as fat — but 'lean mass' isn't the same as muscle.
The most detailed picture comes from body-composition substudies that used DXA scans. In a substudy of SURMOUNT-1, adults with obesity took tirzepatide for 72 weeks. Total fat mass fell by about 34% (roughly 15.9 kg), while lean mass fell by about 11% (roughly 5.6 kg). Put another way, of all the weight lost, about 74% came from fat and about 26% from lean tissue. The authors concluded that this ratio was not disproportionate compared with other obesity treatments, even though the total weight loss was larger.
An exploratory DXA analysis from the STEP 1 trial of semaglutide pointed the same direction: fat mass declined more than lean mass, and lean tissue actually made up a larger share of body weight by the end of 68 weeks. Reported figures put the fat-mass reduction near 19% (about 19.3%), with roughly 40% of total weight lost coming from lean mass. These come from an exploratory body-composition substudy rather than a primary trial endpoint, so they should be read as indicative rather than definitive — but the fat-mass figure matches the published analysis and the overall pattern is consistent.
Across studies, the lean-mass share is genuinely variable. A dedicated review of GLP-1 therapies found it ranges widely — sometimes 15% or less of the weight lost, sometimes 40 to 60%. It is also worth knowing what these scans actually measure. DXA reports "lean mass," which is fat-free mass: muscle plus organs, water, connective tissue and bone-related tissue. It is not the same as skeletal muscle, and the scan cannot isolate muscle on its own. Headlines that treat "lean mass loss" as "muscle loss" are claiming more than the scans can show.
Lean mass is not the same as muscle, and losing tissue mass is not the same as getting weaker.
Mass is not the same as strength
When one study actually measured it, grip strength rose even as the scale's muscle number fell.
This distinction matters because mass and function can move in different directions. A 2025 systematic review of tirzepatide's effects on skeletal muscle highlighted the same gap: the pivotal trials measured tissue mass, and the review called for further study of what those changes mean for muscle strength and physical performance. An MRI substudy from SURPASS-3 even found that muscle fat infiltration went down while fat-free muscle volume dipped only slightly — meaning muscle quality appeared to improve as quantity edged lower. Mass numbers alone, in other words, can be misleading about muscle health.
When a study did measure function, the reassurance grew. In the SEMALEAN study, adults on semaglutide lost about 3.0 kg of lean mass by month seven and then stabilized — yet their handgrip strength rose (about +3.7 kg at seven months and +4.1 kg at twelve months). The share of participants with sarcopenic obesity fell from 49% to 33%. The researchers concluded that functional outcomes held up despite the lower absolute muscle mass. It is a single study, but it is one of the few here that measured strength at all.
How to protect your muscle
Two levers with real support: adequate protein, and resistance or structured exercise.
If some lean loss is expected, the practical question is how to minimize it. The evidence points consistently to two levers: adequate protein and resistance or structured exercise. The GLP-1 lean-mass review frames both as the core mitigation strategy, with protein intakes commonly cited around 1.2 to 1.6 grams per kilogram of body weight per day.
Exercise has the strongest supporting trial. In a randomized study of weight-loss maintenance, combining exercise with liraglutide (an older GLP-1 drug) lowered body-fat percentage roughly twice as much as either approach alone — about 3.9 percentage points for the combination, versus about 1.7 for exercise and 1.9 for the drug. The pattern suggests a useful division of labor: the medication drives fat loss while exercise helps protect lean tissue.
The medication drives the fat loss; exercise is what protects the muscle.
- Prioritize resistance or structured exercise during and after weight loss — the evidence most directly supports it for protecting body composition.
- Aim for adequate protein; intakes around 1.2 to 1.6 g/kg/day are commonly cited in this research.
- Treat these as sensible, not settledmuch of the guidance is extrapolated from general weight-loss and older-drug studies.
One honest caveat sits underneath all of this: much of the muscle-preservation guidance is extrapolated. The stronger evidence for protein and resistance training comes from general weight-loss research and older agents like liraglutide. Few randomized trials have tested these countermeasures directly alongside the newer, more potent drugs. The advice is reasonable, but not yet proven specifically for semaglutide 2.4 mg or tirzepatide.
What we still don't know
The pivotal trials never tested strength or function — and the risk isn't spread evenly.
Several gaps deserve emphasis. The large pivotal trials measured body composition only in small substudies and did not test muscle strength or physical function at all, so the real-world consequences of the mass loss are largely unstudied. Long-term, multi-year data on muscle during GLP-1 treatment are limited. And the concern is not evenly distributed: it is greatest for older adults and others already at risk of sarcopenia or frailty, for whom even modest lean-tissue loss can matter more.
For most people, the current evidence describes GLP-1 weight loss as mostly fat, accompanied by some lean-tissue loss that appears broadly in line with other weight-loss methods — not clearly worse — with early signs that strength and muscle quality can be maintained, especially when exercise and protein are part of the plan. What is still missing is long-term, function-focused data. Until it arrives, the reasonable posture is cautious optimism paired with muscle-protective habits.
- 01 DailyMed / FDA Wegovy (semaglutide) prescribing information, Pharmacodynamics (12.2) dailymed.nlm.nih.gov ↗Regulator statement that semaglutide lowers body weight with greater fat mass loss than lean mass loss. Verified via DailyMed.
- 02 SURMOUNT-1 DXA body-composition substudy, Diabetes, Obesity and Metabolism, 2025 pmc.ncbi.nlm.nih.gov ↗Tirzepatide 72-week DXA substudy: fat mass -33.9% (~15.9 kg), lean mass -10.9% (~5.6 kg); ~74% of weight lost as fat, ~26% as lean; authors report loss not disproportionate vs other treatments.
- 03 STEP 1 exploratory DXA analysis of semaglutide: fat mass -19.3%, increased proportion of lean body mass at 68 weeks; lean mass roughly 40% of total weight lost is an exploratory-substudy estimate.
- 04 Hidalgo Ramos et al., Cureus, 2025 pmc.ncbi.nlm.nih.gov ↗Systematic review of tirzepatide and skeletal muscle mass, including SURPASS-3 MRI: reduced muscle fat infiltration and small fat-free muscle volume change; review calls for further study of strength/physical performance.
- 05 SEMALEAN study, Diabetes, Obesity and Metabolism, 2026 (PubMed 41068996) pmc.ncbi.nlm.nih.gov ↗Semaglutide study: lean mass -3.0 kg by month 7 then stable, handgrip +3.7 kg (M7) and +4.1 kg (M12), sarcopenic obesity 49% to 33%.
- 06 Neeland, Linge, Birkenfeld, Diabetes, Obesity and Metabolism, 2024 (26 Suppl 4:16-27) dom-pubs.onlinelibrary.wiley.com ↗Review of lean-mass change with GLP-1 therapies: lean-mass share of weight lost ranges from ~15% or less to 40-60%; recommends protein 1.2-1.6 g/kg/day and resistance training.
- 07 Lundgren et al., New England Journal of Medicine, 2021 (NEJMoa2028198) pubmed.ncbi.nlm.nih.gov ↗Randomized weight-loss maintenance trial: body-fat percentage fell 3.9 points with exercise+liraglutide, ~twice the exercise-alone (1.7) and liraglutide-alone (1.9) decreases.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
